.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKinsey
Mallinckrodt
Johnson and Johnson
Covington
Cantor Fitzgerald
Boehringer Ingelheim
McKesson
US Army

Generated: December 14, 2017

DrugPatentWatch Database Preview

Nintedanib esylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for nintedanib esylate and what is the scope of nintedanib esylate patent protection?

Nintedanib esylate
is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Nintedanib esylate has one hundred and sixteen patent family members in forty-three countries and ten supplementary protection certificates in eight countries.

There is one drug master file entry for nintedanib esylate. One supplier is listed for this compound.

Pharmacology for nintedanib esylate

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-002Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Boehringer IngelheimOFEVnintedanib esylateCAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: nintedanib esylate

Country Document Number Estimated Expiration
Denmark1224170► Subscribe
Japan2005535684► Subscribe
South Africa200202764► Subscribe
European Patent Office1224170► Subscribe
Japan5039279► Subscribe
Luxembourg92681► Subscribe
Eurasian Patent Organization200500146► Subscribe
Argentina026036► Subscribe
Norway330486► Subscribe
Eurasian Patent Organization200200380► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NINTEDANIB ESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00019Denmark► SubscribePRODUCT NAME: NINTEDANIB, TAUTOMERERNE OG SALTENE DERAF, SAERLIGT NINTEDANIB OG FYSIOLOGISK ACCEPTABLE SALTE DERAF, SPECIFIKT NINTEDANIB ESILAT; REG. NO/DATE: EU/1/14/954/001-004 20141121
90015-2Sweden► SubscribePRODUCT NAME: NINTEDANIB, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE; REG. NO/DATE: EU/1/14/954 20141121
8Finland► Subscribe
15/017Ireland► SubscribePRODUCT NAME: VARGATEF-NINTEDANIB, THE TAUTOMERS AND THE PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
2015015Lithuania► SubscribePRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
2015015,C1224170Lithuania► SubscribePRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
C0024France► SubscribePRODUCT NAME: NINTEDANIB,SES TAUTOMERES ET SES SELS,EN PARTICULIER LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE NINTEDANIB ET PLUS PARTICULIEREMENT L'ESILATE; REGISTRATION NO/DATE: EU/1/14/954 20141125
00725Netherlands► SubscribePRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
0725Netherlands► SubscribePRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141125
681Luxembourg► SubscribePRODUCT NAME: INDOLINONES SUBSTITUEES EN POSITION 6, LEUR PREPARATION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS; FIRST REGISTRATION: 20141121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Covington
Daiichi Sankyo
Accenture
Farmers Insurance
US Department of Justice
Harvard Business School
Merck
Deloitte
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot